Business Description
SCYNEXIS Inc
NAICS : 325412
SIC : 2834
ISIN : US8112921015
Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.33 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.13 | |||||
| Beneish M-Score | -1.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Book Growth Rate | 19.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.63 | |||||
| 9-Day RSI | 27.53 | |||||
| 14-Day RSI | 31.38 | |||||
| 6-1 Month Momentum % | -36.5 | |||||
| 12-1 Month Momentum % | -35.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.13 | |||||
| Quick Ratio | 3.13 | |||||
| Cash Ratio | 2.68 | |||||
| Days Inventory | 290.88 | |||||
| Days Sales Outstanding | 97.79 | |||||
| Days Payable | 148.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.7 | |||||
| Shareholder Yield % | 51.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -71.42 | |||||
| Operating Margin % | -608.57 | |||||
| Net Margin % | -425.41 | |||||
| FCF Margin % | -256.8 | |||||
| ROE % | -50.9 | |||||
| ROA % | -30.26 | |||||
| ROIC % | -142.3 | |||||
| ROC (Joel Greenblatt) % | -1268.04 | |||||
| ROCE % | -36 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.56 | |||||
| PS Ratio | 5.56 | |||||
| PB Ratio | 0.64 | |||||
| Price-to-Tangible-Book | 0.64 | |||||
| EV-to-EBIT | 0.4 | |||||
| EV-to-EBITDA | 0.4 | |||||
| EV-to-Revenue | -1.66 | |||||
| EV-to-FCF | 0.65 | |||||
| Price-to-Net-Current-Asset-Value | 0.95 | |||||
| Price-to-Net-Cash | 1.32 | |||||
| Earnings Yield (Greenblatt) % | 250 | |||||
| FCF Yield % | -58.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SCYNEXIS Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.858 | ||
| EPS (TTM) (€) | -0.7 | ||
| Beta | 1.06 | ||
| Volatility % | 76.68 | ||
| 14-Day RSI | 31.38 | ||
| 14-Day ATR (€) | 0.035294 | ||
| 20-Day SMA (€) | 1.12645 | ||
| 12-1 Month Momentum % | -35.61 | ||
| 52-Week Range (€) | 0.9475 - 2.498 | ||
| Shares Outstanding (Mil) | 37.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SCYNEXIS Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SCYNEXIS Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
SCYNEXIS Inc Frequently Asked Questions
What is SCYNEXIS Inc(FRA:135A)'s stock price today?
The current price of FRA:135A is €0.95. The 52 week high of FRA:135A is €2.50 and 52 week low is €0.95.
When is next earnings date of SCYNEXIS Inc(FRA:135A)?
The next earnings date of SCYNEXIS Inc(FRA:135A) is 2025-03-28 Est..
Does SCYNEXIS Inc(FRA:135A) pay dividends? If so, how much?
SCYNEXIS Inc(FRA:135A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers